Projects

Click on the project acronym in the list at the left (reverse chronological order) or the project name in the summary below for the web site of that project.

Specialized Program of Translational Research in Acute Stroke (SPOTRIAS)

A specialized center program of four phase I and II clinical trials and one epidemiological study. The goal of SPOTRIAS is to reduce disability and mortality in acute stroke patients through the development of improved treatment by laboratory investigation into the biology of stroke, clinical investigation of new therapies based on these laboratory studies, and assessment of outcome and improved application of effective therapies. Secure web applications update the SPOTRIAS database.

Sponsored by the National Institute of Neurological Disorders and Stroke (NINDS); 2002–2007 ($640,877).

Early Treatment for Retinopathy of Prematurity (ETROP)

ETROP is a multicenter study in 26 centers with a natural history study that is determining the incidence of retinopathy of prematurity and a randomized clinical trial that is determining the safety and efficacy of early treatment of retinopathy of prematurity in 400 premature infants.

Sponsored by the National Eye Institute (NEI); 1999–2004 ($10,285,991).

Genetics of Hypertension Associated Treatments (GENHAT)

A prospective study that examines the association between selected hypertensive genes and coronary heart diseases modified by the type of antihypertensive treatment. GENHAT is an ancillary study of ALLHAT (see summary below).

Sponsored by the National Heart, Lung, and Blood Institute (NHLBI); 1999–2004 ($1,474,101).

Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

A practice-based randomized clinical trial of antihypertensive pharmacological treatment in more than 600 office-based practices and general medical and specialty clinics in the U.S., Puerto Rico, the Virgin Islands, and Canada. It had two components:

• An antihypertensive component, to determine whether newer antihypertensive agents, such as ACE inhibitors, calcium blockers, and alpha blockers, reduce incidence of coronary heart disease (CHD) in high-risk hypertensives when compared to diuretics.
• A lipid-lowering component, to determine whether reduction of serum cholesterol with pravastatin, an HMG-CoA reductase inhibitor, reduces total mortality in moderately hypercholesterolemic older hypertensives.

Sponsored by the National Heart, Lung and Blood Institute (NHLBI); 1993–2008 ($101,198,107). Final Papers | Design Paper | All Papers

Light Reduction in Prevention of Retinopathy of Prematurity (LIGHT-ROP)

A randomized, multicenter clinical trial in three centers that determined the efficacy of reduced ambient-light exposure to reduce the incidence of retinopathy of prematurity in 409 premature infants.

Sponsored by the National Eye Institute (NEI); 1995–2000 ($441,535).

Nitro-Dur in Post Myocardial Infarction Patients (NITRO-DUR)

A randomized, double-blind, placebo-controlled, multicenter clinical trial in 30 centers that tested the effectiveness of intermittent transdermal nitroglycerin therapy on left ventricular dilatation and function in 300 post-myocardio infarction patients.

Sponsored by Schering-Plough, Inc.; 1992–1994 ($310,778).

Cholesterol and Recurrent Events Trial (CARE)

A randomized, placebo-controlled, multicenter clinical trial in 80 centers that tested the effectiveness of pravastatin in reducing cardiovascular events in 4,159 post-mycardial infarction patients.

Sponsored by Bristol-Myers-Squibb, Inc.; 1989–2002 ($4,319,394).

Survival and Ventricular Enlargement Study (SAVE)

A randomized, placebo-controlled, multicenter clinical trial in 40 centers that tested the effectiveness of captopril in reducing total mortality and/or ventricular enlargement in 2,231 post-myocardial infarction patients.

Sponsored by Bristol-Myers-Squibb, Inc.; 1986–1993 ($1,959,014).

Cryotherapy for Retinopathy of Prematurity Study (CRYO-ROP)

A randomized multicenter study in 23 centers enrolling 4,099 infants in a natural history study with a randomized clinical trial that determined the safety and efficacy of cryotherapy of the retina in the treatment of retinopathy of prematurity in 291 premature infants.

Sponsored by the National Eye Institute (NEI); 1985–2003 ($4,534,242).

Systolic Hypertension in the Elderly Program (SHEP)

A randomized, multicenter clinical trial in 16 centers which tested the effectiveness of antihypertensive treatment in reducing the combined incidence of fatal and nonfatal stroke in 4,736 elderly patients with isolated systolic hypertension.

National Heart, Lung, and Blood Institute (NHLBI) and
National Institute on Aging (NIA); 1984–1993 ($9,003,630).

Trial of Antihypertensive Interventions and Management (TAIM)

A three-center study of the effectiveness of dietary and pharmacological measures in treating 878 mild hypertensive patients.

Sponsored by the National Heart, Lung and Blood Institute (NHLBI); 1984–1993 ($1,058,316).

Beta-Blocker Heart Attack Trial (BHAT)

A randomized, double-blind, multicenter clinical trial designed to test the effectiveness of propranolol in reducing mortality in 3,837 post-myocardial infarction patients in 31 centers.

Sponsored by the National Heart, Lung and Blood Institute (NHLBI); 1984–1993 ($4,208,443).

Dietary Intervention Study in Hypertension (DISH)

A three-center study of the effectiveness of dietary measures in helping 479 previously treated HDFP participants remain off drug therapy.

Sponsored by the National Heart, Lung and Blood Institute (NHLBI); 1980–1984 ($421,871).

Impact of Hypertension Information (IHI)

A three-center, cross-sectional study of the impact of information about high blood pressure on detection, awareness, and treatment of hypertension in three communities where HDFP clinical centers were located.

Sponsored by the National Heart, Lung and Blood Institute (NHLBI); 1977–1978 (funded in HDFP).

Hypertension Incidence Study (HIS)

A longitudinal study of the three-year incidence of hypertension among 9,500 normotensive persons identified in 13 centers as part of the hypertension screening program of HDFP.

Sponsored by the National Heart, Lung and Blood Institute (NHLBI); 1973–1978 (funded in HDFP).

Hypertension Detection and Follow-up Program (HDFP)

A clinical trial in 14 centers which investigated the differences in mortality and selected morbidity between 10,940 patients randomly allocated to either an intensive hypertension control program or referral back to the regular medical care system.

Sponsored by the National Heart, Lung and Blood Institute (NHLBI); 1971–1993 ($18,059,234).